Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.96
+0.14007.69%
Post-market: 1.95-0.0099-0.51%19:53 EDT
Volume:876.77K
Turnover:1.68M
Market Cap:44.42M
PE:-0.15
High:1.97
Open:1.85
Low:1.82
Close:1.82
52wk High:10.99
52wk Low:1.79
Shares:22.66M
Float Shares:17.07M
Volume Ratio:0.86
T/O Rate:5.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.13
PE(LYR):-0.11

Loading ...

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler

Dow Jones
·
Mar 31

Karyopharm Therapeutics Inc : Piper Sandler Cuts Target Price to $8 From $12

THOMSON REUTERS
·
Mar 30

Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement

Reuters
·
Mar 27

BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds

Reuters
·
Mar 25

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 25

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Benzinga
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Karyopharm Therapeutics Shares Reverse Course; NOW Down 10% Premarket

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Shares up 16% Premarket After Co's Blood Cancer Drug Meets One of Two Main Goals in Late‑Stage Study

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Reuters
·
Mar 24

Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint

TIPRANKS
·
Mar 24

Karyopharm prices USD 30 million private placement with RA Capital

Reuters
·
Mar 24

Karyopharm SENTRY Phase 3 trial in myelofibrosis meets SVR35 endpoint with 22 percentage-point gain at week 24

Reuters
·
Mar 24

Karyopharm Announces $30 Million Private Placement With Ra Capital

THOMSON REUTERS
·
Mar 24

Karyopharm's Phase 3 Sentry Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Inc - to Meet With FDA to Discuss Sentry Trial Data and Potential Snda Filing

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Inc - Sentry Trial Does Not Meet Second Co-Primary Endpoint of Abs-Tss

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Inc - Sentry Trial Shows >50% Reduction in Risk of Death Versus Ruxolitinib

THOMSON REUTERS
·
Mar 24